Disposition and metabolism of the sulfonylurea oncolytic agent LY295501 in mouse, rat, and monkey

Drug Metabolism and Disposition

Volumn 25, Issue 6, 1997, Pages 701-708

  Ehlhardt, William J ^a   Woodland, Joseph M ^b   Toth, John E ^b   Ray, James E ^b   Martin, Diana L ^b  

^a ELI LILLY AND COMPANY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

1 (3,4 DICHLOROPHENYL) 3 (2,3 DIHYDROBENZOFURAN 5 YLSULFONYL)UREA; ANTINEOPLASTIC AGENT; DIHYDROBENZOFURAN DERIVATIVE; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; FEMALE; INTRAGASTRIC DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; RHESUS MONKEY; STOMACH INTUBATION;

ANIMALS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BENZOFURANS; BIOLOGICAL AVAILABILITY; FEMALE; HALF-LIFE; MACACA MULATTA; MALE; METABOLIC CLEARANCE RATE; MICE; MICE, INBRED C3H; PHENYLUREA COMPOUNDS; RATS; RATS, INBRED F344;

ANIMALIA; MACACA MULATTA;

EID: 0030974206     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. J. F. Worzalla, J. R. Bewley, S. B. Gates, M. R. Gross, R. M. Schultz, S. L. Andis, J. E. Toth, J. E. Ray, W. J. Ehlhardt, J. L. Zimmermann, G. B. Boder, and G. B. Grindey: Plasma levels of free drug, cytotoxicity in albumin-free media and antitumor activity for diarylsulfonylurea antitumor agents. Proc. Am. Assoc. Cancer Res. 34, 371 (1993).
2. J. L. Zimmermann, J. F. Worzalla, G. B. Grindey, J. E. Toth, and G. B. Boder: Pre-clinical pharmacology and toxicology of a new oncolytic sulfonylurea compound. LY295501. Proc. Am. Assoc. Cancer Res. 34, 427 (1993).
3. J. L. Zimmermann: Primate and rat toxicology studies conducted on a new oncolytic sulfonylurea compound, LY295501. Proc. Am. Assoc. Cancer Res. 35, 460 (1994).
4. W. J. Ehlhardt: Metabolism and disposition of the anticancer agent sulofenur in mouse, rat, monkey and human. Drug Metab. Dispos. 19, 370-375 (1991).
5. W. J. Ehlhardt, J. L. Zimmermann, J. E. Ray, and J. E. Toth: Formation of indenesulfonylureas in the metabolism of the anticancer agent sulofenur in rats, monkeys and humans. Drug Metab. Dispos. 20, 958-961 (1992).
6. W. J. Ehlhardt, H. R. Sullivan, P. G. Wood, J. M. Woodland, M. Hamilton, C. Hamilton, D. Cornprobst, G. B. Grindey, J. F. Worzalla, J. R. Bewley, G. C. Todd, and J. J. Howbert: Pharmacokinetics of the anticancer agent sulofenur in mice, rats, monkeys and dogs. J. Pharmaceut. Sci. 82, 683-688 (1993).
7. W. J. Ehlhardt, J. M. Woodland, J. F. Worzalla, J. R. Bewley, G. B. Grindey, G. C. Todd, J. E. Toth, and J. J. Howbert: Comparison of metabolism and toxicity to the structure of the anticancer agent sulofenur and related diarylsulfonylureas. Chem. Res. Toxicol. 5, 667-673 (1992).
8. J. J. Howbert, C. S. Grossman, T. A. Crowell, B. J. Rieder, R. W. Harper, K. E. Kramer, E. V. Tao, J. Aikens, G. A. Poore, S. M. Rinzel, G. B. Grindey, W. N. Shaw, and G. C. Todd: Novel agents effective against solid tumors: the diarylsulfonylureas. Synthesis, activities, and analysis of quantitative structure-activity relationships. J. Med. Chem. 33, 2393-2407 (1990).
9. A. Lestas, D. Button, S. Hatty, S. Hussain, S. Tan, J. Walling, and A. J. Bellingham: Study of the mechanism of induction of methemoglobinemia and anemia by sulofenur (LY186641). Ann. Oncol. 1, (Suppl.) 41 (1990).
10. D. C. Moltrip, R. H. Wheeler, K. M. Hall, and J. T. Prachal: Evaluation of the methemoglobinemia associated with sulofenur. Invest. New Drugs 12, 99-102 (1994).
11. M. Kiese: "Methemoglobinemia: A Comprehensive Treatise." CRC Press, Cleveland OH, 1974.
12. J. E. Toth, G. B. Grindey, W. J. Ehlhardt, J. E. Ray, G. B. Boder, J. R. Bewley, K. K. Klingerman, S. B. Gates, C. S. Grossman, S. M. Rinzel, R. M. Schultz, L. C. Weir, J. F. Worzalla, J. L. Zimmermann, and J. J. Howbert: SAR studies on the oncolytic diarylsulfonylureas. The selection of LY295501 as a clinical candidate. J. Med. Chem., 40, 1018-1025 (1997).
13. J. E. Toth, J. E. Ray, and W. J. Ehlhardt, "The Synthesis of o-aminophenyl sulfate metabolites of the oncolytic sulfonylureas." Bioorg. Med. Chem. 2, 1013-1014 (1992).
14. W. J. Ehlhardt, and J. J. Howbert: Metabolism and disposition of p-chloroaniline in rat, mouse and monkey. Drug Metab. Dispos. 19, 366-369 (1991).
15. F. V. Fossella, S. M. Lippman, D. E. Seitz, D. S. Alberts, C. W. Taylor, E. Wiltshaw, J. Hardy, M. O'Brien, T. R. Haynes, and R. L. Wolen: Hypoprothrombinemia from coadministration of sulofenur (LY186641) and warfarin: report of three cases. Invest. New Drugs 9, 357-359 (1991).
16. C. K. Lau, P. C. Belanger, C. DuFresne, J. Scheigetz, M. Therien, B. Fitzsimmons, R. N. Young, A. W. Ford-Hutchinson, D. Riendeau, D. Denis, J. Guay, S. Charleson, H. Piechuta, C. S. McFarlane, S.-H. L. Chiu, D. Eline, R. F. Alvaro, G. Miwa, and J. L. Walsh: Development of 2,3-dihydro-6-(3-phenoxypropyl)-2-(2-phenylethyl)-5-benzofuranol (L-670,630) as a potent and orally active inhibitor of 5-lipoxygenase. J. Med. Chem. 35, 1299-1318 (1992).
17. D. C. McMillan, T. P. Bradshaw, J. A. Hinson, and D. J. Jollow: Role of metabolites in propanil-induced hemolytic anemia. Toxicol. Appl. Pharmacol. 110, 70-78 (1991).